Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL) is gaining momentum and
demonstrating durable responses in patients with advanced melanoma. Although …

After a positive phase III trial, it is evident that treatment with tumor-infiltrating lymphocytes
(TIL) is a safe, feasible, and effective treatment modality for patients with metastatic …

Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective
treatment for patients with metastatic melanoma. With higher response rates than ipilimumab …

Adoptive T-cell therapy (ACT) using expanded autologous tumor-infiltrating lymphocytes
(TIL) and tumor antigen-specific T cell expanded from peripheral blood are complex but …

Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF
and MEK inhibitors have revolutionized the treatment of melanoma over the past decade …

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with
lymphodepletion and high-dose interleukin 2 has shown reproducible objective response …

Background Immune checkpoint inhibitors and targeted therapies have dramatically
improved outcomes in patients with advanced melanoma, but approximately half these …

Immunotherapy using autologous T cells has emerged to be a powerful treatment option for
patients with metastatic melanoma. These include the adoptive transfer of autologous tumor …

Over the past few years melanoma incidence has been rising steadily, resulting in an
increase in melanoma related mortality. Until recently, therapeutic options for metastatic …

Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has
shown remarkable results in malignant melanoma (MM), while studies on the potential in …